-
1.发明授权Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy 有权四氢异喹啉，含有它们的药物组合物及其在治疗中的应用公开(公告)号：US08957089B2
公开(公告)日：2015-02-17
申请号：US13792105
申请日：2013-03-10
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Wilfried Braje , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles Hutchins
IPC分类号： C07D217/18 , C07D401/04 , A61K31/44 , C07D401/06 , C07D401/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D498/04 , C07D513/04 , C07D401/08
CPC分类号： C07D217/18 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D498/04 , C07D513/04
摘要： The present invention relates to tetrahydroisoquinoline of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such tetrahydroisoquinolines, and the use of such tetrahydroisoquinolines for therapeutic purposes. The tetrahydroisoquinolines are GlyT1 inhibitors.
摘要翻译： 本发明涉及式（I）的四氢异喹啉或其生理上耐受的盐。 本发明涉及包含这种四氢异喹啉的药物组合物以及用于治疗目的的这种四氢异喹啉的用途。 四氢异喹啉是GlyT1抑制剂。
-
公开(公告)号：US10556907B2
公开(公告)日：2020-02-11
申请号：US15248994
申请日：2016-08-26
发明人： Udo Lange , Michael Ochse , Elizabeth van der Kam , Jeroen van Bergeijk , Sean Turner , Frank Oellien , Patrick Walleser , Wilhelm Amberg , Wilfried Hornberger , Herve Geneste , Mario Mezler , Charles Hutchins
IPC分类号： C07D487/04 , C07D471/04
摘要： The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
-
3.发明申请公开(公告)号：US20190233510A1
公开(公告)日：2019-08-01
申请号：US16055659
申请日：2018-08-06
发明人： Mario Mezler , Achim Moeller , Reinhold Mueller , Bernhard K. Mueller , Tariq Ghayur , Eve H. Barlow , Martin Schmidt , Axel Meyer , Nicole Teusch
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/28 , A61K39/3955 , A61K2039/505 , C07H21/00 , C07K16/2863 , C07K2317/14 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
-
4.发明申请PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 审中-公开PHENALKYLAMINE衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20150158842A1
公开(公告)日：2015-06-11
申请号：US14617737
申请日：2015-02-09
发明人： Frauke Pohlki , Udo Lange , Wilhelm Amberg , Michael Ochse , Berthold Behl , Charles W. Hutchins , Wilfried Hornberger , Mario Mezler
IPC分类号： C07D401/12
CPC分类号： C07D401/12 , A61K31/357 , A61K31/472 , A61K31/4725 , A61K31/538 , C07D217/02 , C07D217/08 , C07D217/22 , C07D217/26
摘要： The present invention relates to phenalkylamine derivatives of the formula (I) or (II) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such phenalkylamine derivatives, and the use of such phenalkylamine derivatives for therapeutic purposes. The phenalkylamine derivatives are GlyT1 inhibitors.
摘要翻译： 本发明涉及式（I）或（II）的苯烷基胺衍生物或其生理上耐受的盐。 本发明涉及包含这种苯烷基胺衍生物的药物组合物，以及这种苯烷基胺衍生物用于治疗目的的用途。 酚烷基胺衍生物是GlyT1抑制剂。
-
5.发明申请NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF 审中-公开去除NOGO-66受体（NgR）的单克隆抗体及其用途公开(公告)号：US20160145334A1
公开(公告)日：2016-05-26
申请号：US14989532
申请日：2016-01-06
发明人： Mario Mezler , Achim Moeller , Reinhold Mueller , Bernhard K. Mueller , Tariq Ghayur , Eve H. Barlow , Martin Schmidt , Axel Meyer , Nicole Teusch
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/28 , A61K39/3955 , A61K2039/505 , C07H21/00 , C07K16/2863 , C07K2317/14 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
摘要翻译： 本发明涉及结合Nogo-66受体的分离的蛋白质，特别是单克隆抗体。 具体地说，这些抗体具有抑制Nogo-66受体的天然配体结合并中和Nogo-66受体的能力。 本发明的这些抗体或其部分可用于检测NgR和抑制NgR活性，例如在患有NgR或Nogo-66活性有害的病症的人中。
-
公开(公告)号：US20170057966A1
公开(公告)日：2017-03-02
申请号：US15248994
申请日：2016-08-26
发明人： Udo Lange , Michael Ochse , Elizabeth van der Kam , Jeroen van Bergeijk , Sean Turner , Frank Oellien , Patrick Walleser , Wilhelm Amberg , Wilfried Hornberger , Herve Geneste , Mario Mezler , Charles Hutchins
IPC分类号： C07D487/04 , C07D471/04
CPC分类号： C07D487/04 , C07D471/04
摘要： The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
摘要翻译： 本发明涉及作为S1P调节剂的杂环化合物，包含这些化合物的药物组合物及其用于治疗，缓解或预防由S1P受体介导的疾病或病症的用途。
-
7.发明授权Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权氨基四氢萘衍生物，含有它们的药物组合物及其在治疗中的应用公开(公告)号：US09096619B2
公开(公告)日：2015-08-04
申请号：US13789967
申请日：2013-03-08
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC分类号： A61K31/135 , C07C211/27 , A61K31/16 , C07C215/70 , C07F7/08 , C07D295/135 , C07D265/30 , C07D403/12 , C07D207/09 , C07D205/04 , C07D305/08 , C07C271/24 , C07C311/13 , C07C317/28 , C07D213/71 , C07C255/58 , C07D231/18 , C07C307/06 , C07D333/34 , C07C309/65 , C07D233/84 , C07C311/05 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C215/64 , C07C217/74 , C07D249/12 , C07C233/18 , C07C233/19 , C07D261/08 , C07C233/69 , C07D207/10 , C07D207/12 , C07D207/27 , C07D275/02 , C07D207/36 , C07D207/48 , C07D295/096
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
摘要翻译： 本发明涉及式（I）的氨基四氢化萘衍生物或其生理上耐受的盐。 本发明涉及包含这种氨基四氢化萘衍生物的药物组合物，以及这种氨基四氢化萘衍生物用于治疗目的的用途。 氨基四氢叶酸衍生物是GlyT1抑制剂。
-
8.发明申请AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权氨基嘌呤衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20130184238A1
公开(公告)日：2013-07-18
申请号：US13789967
申请日：2013-03-08
发明人： Wilhelm Amberg , Michael Ochse , Udo Lange , Andreas Kling , Berthold Behl , Wilfried Hornberger , Mario Mezler , Charles W. Hutchins
IPC分类号： C07F7/08 , C07D265/30 , C07D403/12 , C07C317/28 , C07D205/04 , C07D305/08 , C07C271/24 , C07C311/13 , C07D295/135 , C07D207/09
CPC分类号： C07C311/05 , C07C215/64 , C07C217/74 , C07C233/18 , C07C233/19 , C07C233/69 , C07C255/58 , C07C271/24 , C07C307/06 , C07C309/65 , C07C311/07 , C07C311/09 , C07C311/10 , C07C311/13 , C07C311/14 , C07C311/17 , C07C311/18 , C07C311/20 , C07C311/24 , C07C317/18 , C07C317/28 , C07C2601/02 , C07C2601/04 , C07C2602/10 , C07D205/04 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/36 , C07D207/48 , C07D213/71 , C07D231/18 , C07D233/84 , C07D249/12 , C07D261/08 , C07D265/30 , C07D275/02 , C07D295/096 , C07D295/135 , C07D305/08 , C07D333/34 , C07D401/12 , C07D403/12 , C07D409/12 , C07F7/081
摘要： The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
摘要翻译： 本发明涉及式（I）的氨基四氢化萘衍生物或其生理上耐受的盐。 本发明涉及包含这种氨基四氢化萘衍生物的药物组合物，以及这种氨基四氢化萘衍生物用于治疗目的的用途。 氨基四氢叶酸衍生物是GlyT1抑制剂。
-
公开(公告)号：US10040852B2
公开(公告)日：2018-08-07
申请号：US14989532
申请日：2016-01-06
发明人： Mario Mezler , Achim Moeller , Reinhold Mueller , Bernhard K. Mueller , Tariq Ghayur , Eve H. Barlow , Martin Schmidt , Axel Meyer , Nicole Teusch
IPC分类号： C07K16/28 , A61K39/395 , C07H21/00 , A61K39/00
摘要： The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
-
10.发明授权Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof 有权针对Nogo-66受体（NgR）的中和单克隆抗体及其用途公开(公告)号：US09255146B2
公开(公告)日：2016-02-09
申请号：US14013916
申请日：2013-08-29
发明人： Mario Mezler , Achim Moeller , Reinhold Mueller , Bernhard K. Mueller , Tariq Ghayur , Eve H. Barlow , Martin Schmidt , Axel Meyer , Nicole Teusch
CPC分类号： C07K16/28 , A61K39/3955 , A61K2039/505 , C07H21/00 , C07K16/2863 , C07K2317/14 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
摘要翻译： 本发明涉及结合Nogo-66受体的分离的蛋白质，特别是单克隆抗体。 具体地说，这些抗体具有抑制Nogo-66受体的天然配体结合并中和Nogo-66受体的能力。 本发明的这些抗体或其部分可用于检测NgR和抑制NgR活性，例如在患有NgR或Nogo-66活性有害的病症的人中。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.037 秒)
